InVivo Therapeutics Receives FDA Conditional Approval for Proposed Protocol Changes

By: Benzinga
InVivo Therapeutics (OTC: NVIV ) announced today that it has received conditional approval from the Food and Drug Administration for proposed changes to the protocol and supporting documents for the
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.